Dsuvia Gets Warning Letter As US FDA’s Opioid Decisions Complicate Commissioner Race

 
• By Sarah Karlin-Smith
The Dsuvia warning letter drew a lot of attention from FDA officials.

More from US FDA

More from Agency Leadership